| HAL : inserm-00138277, version 1 |
| PubMed : 17363580 |
| DOI : 10.1158/0008-5472.CAN-06-3947 |
| Fiche détaillée | Récupérer au format |
|
|
| Cancer Res 67, 6 (2007) 2611-6 |
|
|
|
|
| Association of CYP1B1 Germ Line Mutations with Hepatocyte Nuclear Factor 1{alpha}-Mutated Hepatocellular Adenoma. |
|
|
| Emmanuelle Jeannot 1, 2Karine Poussin 1, 2 |
|
|
| (15/03/2007) |
|
|
| Biallelic somatic mutations of TCF1 coding for hepatocyte nuclear factor 1alpha (HNF1alpha) are found in 50% of the hepatocellular adenoma (HCA) cases usually associated with oral contraception. In rare cases, HNF1alpha germ line mutations could also predispose to familial adenomatosis. In order to identify new genetic factors predisposing to HNF1alpha-mutated HCA, we searched for mutations in genes involved in the metabolism of estrogen. For 10 genes (CYP1A1, CYP1A2, CYP3A4, CYP3A5, COMT, UGT2B7, NQO1, GSTM1, GSTP1, and GSTT1), we did not find mutations nor differences in the allele distribution among 32 women presenting HNF1alpha-mutated adenomas compared with 58 controls. In contrast, we identified a CYP1B1 germ line heterozygous mutation in 4 of 32 women presenting HNF1alpha-mutated adenomas compared with none in 58 controls. We confirmed these results with the identification of four additional CYP1B1 mutations in a second series of 26 cases. No mutations were found in the control group, which was extended to 98 individuals, and only a known rare genetic variant was observed in two controls (P = 0.0003). We did an ethoxyresorufin O-deethylase assay to evaluate the functional consequence of the CYP1B1 mutations. We found reduced enzymatic activity in each CYP1B1 variant. In addition, an E229K CYP1B1 mutation was found in a woman with a germ line HNF1alpha mutation in a familial adenomatosis context. In this large family, all three patients with adenomatosis bore both HNF1 and CYP1B1 germ line mutations. In conclusion, our data suggested that CYP1B1 germ line-inactivating mutations might increase the incidence of HCA in women with HNF1alpha mutations. [Cancer Res 2007;67(6):2611-6]. |
|
|
|
|
|
|
|
|
|
|
| 1 : | Genomique Fonctionnelle des Tumeurs Solides |
| INSERM : U674 – Université Paris VII - Paris Diderot – IFR105 | |
| 2 : | Centre d'Etude du Polymorphisme Humain (CEPH) |
| Institut Universitaire d'Hématologie – Fondation Jean Dausset – Université Paris VII - Paris Diderot | |
| 3 : | Service de chirurgie |
| CHU Caen | |
| 4 : | Service de gastro-entérologie |
| Hôpital Armand Trousseau – Assistance publique - Hôpitaux de Paris (AP-HP) – Université Pierre et Marie Curie (UPMC) - Paris VI | |
| 5 : | Laboratoire de Pathologie Cellulaire |
| CHU Grenoble | |
| 6 : | Service d'hépato-gastro-entérologie |
| Assistance publique - Hôpitaux de Paris (AP-HP) – Hôpital Bicêtre – Université Paris XI - Paris Sud | |
| 7 : | Service d'anatomie et cytologie pathologiques [Mondor] |
| Assistance publique - Hôpitaux de Paris (AP-HP) – Hôpital Henri Mondor – Université Paris-Est Créteil Val-de-Marne (UPEC) | |
| 8 : | Service de Cytogénétique |
| Assistance publique - Hôpitaux de Paris (AP-HP) – Hôpital Saint-Antoine – Université Pierre et Marie Curie (UPMC) - Paris VI | |
| 9 : | Bases moléculaires de la réponse aux xénobiotiques |
| INSERM : U775 – CNRS : IFR95 – Université Paris V - Paris Descartes | |
| 10 : | Fibrose hépatique et cancer du foie |
| INSERM : U889 – Université Victor Segalen - Bordeaux II – IFR66 | |
|
|
|
|
|
|
|
|
| domaine | : | Sciences du Vivant/Médecine humaine et pathologie/Hépatologie et Gastroentérologie |
|
|
| CYP1B1 – cytochrome P450 – hepatocellular adenoma – tumor suppressor gene – mutation – genetic predisposition – estrogen – metabolism |
|
|
| Liste des fichiers attachés à ce document : | |||||
|
|
|
| inserm-00138277, version 1 | |
| http://www.hal.inserm.fr/inserm-00138277 | |
| oai:www.hal.inserm.fr:inserm-00138277 | |
| Contributeur : Jessica Zucman-Rossi | |
| Soumis le : Vendredi 4 Septembre 2009, 14:09:15 | |
| Dernière modification le : Vendredi 4 Septembre 2009, 14:09:15 | |